Akeso and Inovio Pharmaceuticals Partner to Develop Combination Therapy for Glioblastoma
Akeso and Inovio Pharmaceuticals have entered into a clinical collaboration to evaluate cadonilimab with INO-5412 in glioblastoma. The combination will be studied in the phase-II INSIGhT trial sponsored by Dana-Farber Cancer Institute, building on prior positive data.
Dr Michael Sumner | 05/03/2026 | By Akanki | 112
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy